Document:

Exhibit
10.2

 

EXECUTION
VERSION

 

THIS
NOTE AND THE INDEBTEDNESS EVIDENCED HEREBY ARE SUBORDINATE IN THE MANNER AND TO THE EXTENT SET FORTH IN THAT CERTAIN SUBORDINATION
AGREEMENT (THE “SVB SUBORDINATION AGREEMENT”) DATED AS OF THE DATE HEREOF BY AND AMONG LENDER, BORROWER, SILICON VALLEY
BANK AND THE OTHER PARTIES THERETO TO THE SENIOR DEBT (AS DEFINED IN THE SVB SUBORDINATION AGREEMENT). THIS NOTE AND THE INDEBTEDNESS
EVIDENCED HEREBY ARE ALSO SUBORDINATE IN THE MANNER AND TO THE EXTENT SET FORTH IN THAT CERTAIN SUBORDINATION AGREEMENT (THE “PFG
SUBORDINATION AGREEMENT,” AND TOGETHER WITH THE SVB SUBORDINATION AGREEMENT, THE “SUBORDINATION AGREEMENTS”)
DATED AS OF THE DATE HEREOF BY AND AMONG LENDER, BORROWER, PARTNERS FOR GROWTH IV, L.P. AND THE OTHER PARTIES THERETO TO THE SENIOR
DEBT (AS DEFINED IN THE PFG SUBORDINATION AGREEMENT); AND THE HOLDER OF THIS NOTE, BY ITS ACCEPTANCE HEREOF, SHALL BE BOUND BY
THE PROVISIONS OF THE SUBORDINATION AGREEMENTS.

 

Promissory
Note

 

September
18, 2018

 

FOR
VALUE RECEIVED, the undersigned (the “Borrower”), hereby promises to pay to NovellusDX, Ltd., or its registered
assigns (the “Lender”), in accordance with the provisions of the Credit Agreement (as hereinafter defined),
the principal amount of each Loan from time to time made by the Lender to the Borrower under that certain Credit Agreement, dated
as of September 14, 2018 (as amended, restated, extended, supplemented or otherwise modified in writing from time to time, the
“Credit Agreement;” the terms defined therein being used herein as therein defined unless otherwise defined
herein), by and between the Borrower and the Lender.

 

The
Borrower promises to pay interest on the unpaid principal amount of each Loan made by the Lender from the date of such Loan until
such principal amount is paid in full, at such interest rates and at such times as provided in the Credit Agreement. All payments
of principal and interest shall be made to the Lender in Dollars in immediately available funds. If any principal amount is not
paid in full when due hereunder, such unpaid amount shall bear interest from the due date thereof until the date of actual payment
(and before as well as after judgment) computed at the per annum rate set forth in the Credit Agreement.

 

This
Note and all amounts outstanding hereunder shall be convertible into Conversion Shares in accordance with the terms and conditions
of the Credit Agreement.

 

This
Note is the Note referred to in the Credit Agreement and the holder is entitled to the benefits thereof. Each Loan made by the
Lender shall be evidenced by one or more loan accounts or records maintained by the Lender in the ordinary course of business.
The Lender may also endorse on Schedule I hereto the date, amount and maturity of its Loans and payments with respect thereto.

 

The
Borrower, for itself, its successors and assigns, hereby waives diligence, presentment, protest and demand and notice of protest,
demand, dishonor and non-payment of this Note.

 

Delivery
of an executed counterpart of a signature page of this Note by fax transmission or other electronic mail transmission (e.g. “pdf”
or “tif”) shall be effective as delivery of a manually executed counterpart of this Note.

 

[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK]

 

    	 	 	 

    	 

    

 

THIS
NOTE SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE.

 

	 	cancer genetics, inc.,
	 	a Delaware corporation
	 	 	 
	 	By:	/s/
    John A. Roberts
	 	Name: 	John
    A. Roberts
	 	Title:	Chief
    Executive Officer

 

[Signature
Page to Promissory Note]Exhibit 10.3

 

EXECUTION
VERSION

 

REGISTRATION
RIGHTS AGREEMENT

 

This
Registration Rights Agreement (this “Agreement”) is made and entered into as of this 18th day of
September, 2018, by and among Cancer Genetics, Inc., a Delaware corporation (the “Company”), and NovellusDX,
Ltd., a company established under the laws of the State of Israel (“NDX”). Capitalized terms used herein have
the respective meanings ascribed thereto in that certain Credit Agreement, dated as of the date hereof, by and between the Company
and NDX (the “Credit Agreement”), unless otherwise defined herein.

 

The
parties hereby agree as follows:

 

1. Certain
Definitions.

 

As
used in this Agreement, the following terms shall have the following meanings:

 

“Prospectus”
means (i) any prospectus (preliminary or final) included in any Registration Statement, as amended or supplemented by any prospectus
supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by such Registration
Statement and by all other amendments and supplements to the prospectus, including post-effective amendments and all material
incorporated by reference in such prospectus, and (ii) any “free writing prospectus” as defined in Rule 405 under
the Securities Act.

 

“Register,”
“registered” and “registration” refer to a registration made by preparing and filing a Registration
Statement or similar document in compliance with the Securities Act (as defined below), and the declaration or ordering of effectiveness
of such Registration Statement or document.

 

“Registrable
Securities” means (i) the Conversion Shares, and (ii) any other securities issued or issuable with respect to or in
exchange for the Conversion Shares, whether by merger, charter amendment, or otherwise; provided that, a security shall
cease to be a Registrable Security (and the Company shall not be required to maintain the effectiveness of any, or file another,
Registration Statement hereunder with respect thereto) for so long as (a) a Registration Statement with respect to the sale of
such Registrable Securities is declared effective by the SEC under the Securities Act and such Registrable Securities have been
disposed of by the holder thereof in accordance with such effective Registration Statement, (b) such Registrable Securities have
been previously sold in accordance with Rule 144, or (c) such securities become eligible for resale without volume or manner-of-sale
restrictions and without current public information pursuant to Rule 144 as set forth in a written opinion letter to such effect,
addressed, delivered and acceptable to the Company’s transfer agent for the Borrower Common Stock (the “Transfer
Agent”), and the affected holders (assuming that such securities and any securities issuable upon exercise, conversion
or exchange of which, or as a dividend upon which, such securities were issued or are issuable, were at no time held by any Affiliate
of the Company, as reasonably determined by the Company, upon the advice of counsel to the Company and the Transfer Agent has
issued certificates for such Registrable Securities to the holder thereof, or as such holder may direct, without any restrictive
legend.

 

“Registration
Statement” means any registration statement of the Company filed under the Securities Act that covers the resale of
any of the Registrable Securities pursuant to the provisions of this Agreement, amendments and supplements to such Registration
Statement, including post-effective amendments, all exhibits and all material incorporated by reference in such Registration Statement.

 

    	 	 	 

    	 

    

 

2. Registration.

 

(a) Registration
Statement. Promptly following NDX’s delivery of the Conversion Notice, but no later than forty-five (45) days
after such delivery (the “Filing Deadline”), the Company shall prepare and file with the SEC one
Registration Statement on Form S-3 (or, if Form S-3 is not then available to the Company or such form of registration is then
available to effect a registration for resale of the Registrable Securities), covering the resale of the Registrable
Securities. Subject to any SEC comments, such Registration Statement shall include the plan of distribution attached hereto
as Exhibit A; provided, however, that NDX shall not be named as an “underwriter” in the
Registration Statement without NDX’s prior written consent. Such Registration Statement also shall cover, to the extent
allowable under the Securities Act and the rules promulgated thereunder (including Rule 416), such indeterminate number of
additional shares of Borrower Common Stock resulting from stock splits, stock dividends or similar transactions with respect
to the Registrable Securities. Such Registration Statement shall not include any shares of Borrower Common Stock or other
securities for the account of any other holder without the prior written consent of NDX. The Registration Statement (and each
amendment or supplement thereto, and each request for acceleration of effectiveness thereof) shall be provided in accordance
with Section 3(c) to NDX and its counsel prior to its filing or other submission. If a Registration Statement covering the
Registrable Securities is not filed with the SEC on or prior to the Filing Deadline, then in addition to any other rights NDX
may have hereunder or under applicable law, the Company will make a payment to NDX, as liquidated damages and not as a
penalty, in an amount equal to 1.5% of the aggregate amount of the Loan made by NDX pursuant to the Credit Agreement for each
30-day period or pro rata for any portion thereof following the Filing Deadline for which no Registration Statement is filed
with respect to the Registrable Securities; up to a maximum remedy of 6% of the aggregate amount of the Loan.

 

(b) Expenses.
The Company will pay all expenses associated with effecting the registration of the Registrable Securities, including filing
and printing fees, the Company’s counsel and accounting fees and expenses, costs associated with clearing the
Registrable Securities for sale under applicable state securities laws, and listing fees, but excluding discounts,
commissions, fees of underwriters, selling brokers, dealer managers or similar securities industry professionals with respect
to the Registrable Securities being sold.

 

(c) Effectiveness.

 

(i)
The Company shall use commercially reasonable efforts to have any Registration Statement declared effective as soon as
practicable. The Company shall notify NDX by facsimile or e-mail as promptly as practicable, and in any event, within
twenty-four (24) hours, after any Registration Statement is declared effective and shall simultaneously provide NDX with
copies of any related Prospectus to be used in connection with the sale or other disposition of the securities covered
thereby.

 

    	 	-2-	 

    	 

    

 

(ii)
For not more than thirty (30) consecutive days or for a total of not more than sixty (60) days in any twelve (12) month
period, the Company may suspend the use of any Prospectus included in any Registration Statement contemplated by this Section
in the event that the Company determines in good faith that such suspension is necessary to (A) delay the disclosure of
material non-public information concerning the Company, the disclosure of which at the time is not, in the good faith opinion
of the Company, in the best interests of the Company or (B) amend or supplement the affected Registration Statement or the
related Prospectus so that such Registration Statement or Prospectus shall not include an untrue statement of a material fact
or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the case of
the Prospectus in light of the circumstances under which they were made, not misleading (an “Allowed
Delay”); provided that the Company shall promptly (a) notify NDX in writing of the commencement of an
Allowed Delay, but shall not (without the prior written consent of NDX) disclose to NDX any material non-public information
giving rise to an Allowed Delay, (b) advise NDX in writing to cease all sales under the Registration Statement until the end
of the Allowed Delay and (c) use commercially reasonable efforts to terminate an Allowed Delay as promptly as
practicable.

 

(d) Rule
415; Cutback. If at any time the SEC takes the position that the offering of some or all of the Registrable Securities
in a Registration Statement is not eligible to be made on a delayed or continuous basis under the provisions of Rule 415
under the Securities Act or requires NDX to be named as an “underwriter”, the Company shall use its best efforts
to persuade the SEC that the offering contemplated by a Registration Statement is a bona fide secondary offering and not an
offering “by or on behalf of the issuer” as defined in Rule 415 and that NDX is not an “underwriter”.
NDX shall have the right to participate or have its counsel participate in any meetings or discussions with the SEC regarding
the SEC’s position and to comment or have its counsel comment on any written submission made to the SEC with respect
thereto. No such written submission shall be made to the SEC to which NDX’s counsel reasonably objects. In the event
that, despite the Company’s best efforts and compliance with the terms of this Section 2(d), the SEC refuses to alter
its position, the Company shall (i) remove from the Registration Statement such portion of the Registrable Securities (the
“Cut Back Shares”) and/or (ii) agree to such restrictions and limitations on the registration and resale
of the Registrable Securities as the SEC may require to assure the Company’s compliance with the requirements of Rule
415 (collectively, the “SEC Restrictions”); provided, however, that the Company shall not
agree to name NDX as an “underwriter” in such Registration Statement without the prior written consent of NDX. No
liquidated damages shall accrue as to any Cut Back Shares until such date as the Company is able to effect the registration
of such Cut Back Shares in accordance with any SEC Restrictions (such date, the “Restriction Termination
Date” of such Cut Back Shares). From and after the Restriction Termination Date applicable to any Cut Back Shares,
all of the provisions of this Section 2 (including the liquidated damages provisions) shall again be applicable to such Cut
Back Shares; provided, however, that (i) the Filing Deadline for the Registration Statement including such Cut
Back Shares shall be ten (10) Business Days after such Restriction Termination Date, and (ii) the date by which the Company
is required to obtain effectiveness with respect to such Cut Back Shares under Section 2(c) shall be the 60th day
immediately after the Restriction Termination Date.

 

    	 	-3-	 

    	 

    

 

3. Company
Obligations. The Company will use commercially reasonable efforts to effect the registration of the Registrable
Securities in accordance with the terms hereof, and pursuant thereto the Company will, as expeditiously as
possible:

 

(a)
use commercially reasonable efforts to cause such Registration Statement to become effective and to remain continuously
effective for a period that will terminate upon the earlier of (i) the date on which all Registrable Securities covered by
such Registration Statement as amended from time to time, have been sold or otherwise disposed of pursuant to the
Registration Statement or in a transaction in which the transferee receives freely tradable shares., and (ii) the date on
which the Registrable Securities no longer constitute “Registrable Securities” pursuant to the definition thereof
(the “Effectiveness Period”) and advise NDX in writing when the Effectiveness Period has
expired;

 

(b)
prepare and file with the SEC such amendments and post-effective amendments to the Registration Statement and the Prospectus
as may be necessary to keep the Registration Statement effective for the Effectiveness Period and to comply with the
provisions of the Securities Act and the Exchange Act with respect to the distribution of all of the Registrable Securities
covered thereby;

 

(c)
provide copies to and permit counsel designated by NDX to review each Registration Statement and all amendments and
supplements thereto no fewer than seven (7) days prior to its filing with the SEC and not file any document to which such
counsel reasonably objects;

 

(d)
furnish to NDX and its legal counsel (i) promptly after the same is prepared and publicly distributed, filed with the SEC, or
received by the Company (but not later than two (2) Business Days after the filing date, receipt date or sending date, as the
case may be) one (1) copy of any Registration Statement and any amendment thereto, each preliminary prospectus and Prospectus
and each amendment or supplement thereto, and each letter written by or on behalf of the Company to the SEC or the staff of
the SEC, and each item of correspondence from the SEC or the staff of the SEC, in each case relating to such Registration
Statement (other than any portion thereof which contains information for which the Company has sought confidential
treatment), and (ii) such number of copies of a Prospectus, including a preliminary prospectus, and all amendments and
supplements thereto and such other documents as NDX may reasonably request in order to facilitate the disposition of the
Registrable Securities owned by NDX that are covered by the related Registration Statement;

 

(e)
use commercially reasonable efforts to (i) prevent the issuance of any stop order or other suspension of effectiveness and,
(ii) if such order is issued, obtain the withdrawal of any such order at the earliest possible moment;

 

(f)
prior to any public offering of Registrable Securities, use commercially reasonable efforts to register or qualify or
cooperate with NDX and its counsel in connection with the registration or qualification of such Registrable Securities for
offer and sale under the securities or blue sky laws of such jurisdictions requested by NDX and do any and all other
commercially reasonable acts or things necessary or advisable to enable the distribution in such jurisdictions of the
Registrable Securities covered by the Registration Statement; provided, however, that the Company shall not be
required in connection therewith or as a condition thereto to (i) qualify to do business in any jurisdiction where it would
not otherwise be required to qualify but for this Section 3(f), (ii) subject itself to general taxation in any jurisdiction
where it would not otherwise be so subject but for this Section 3(f), or (iii) file a general consent to service of process
in any such jurisdiction;

 

    	 	-4-	 

    	 

    

 

(g)
use commercially reasonable efforts to cause all Registrable Securities covered by a Registration Statement to be listed on
each securities exchange, interdealer quotation system or other market on which similar securities issued by the Company are
then listed;

 

(h)
immediately notify NDX, at any time prior to the end of the Effectiveness Period, upon discovery that, or upon the happening
of any event as a result of which, the Prospectus includes an untrue statement of a material fact or omits to state any
material fact required to be stated therein or necessary to make the statements therein not misleading in light of the
circumstances then existing, and promptly prepare, file with the SEC and furnish to NDX a supplement to or an amendment of
such Prospectus as may be necessary so that such Prospectus shall not include an untrue statement of a material fact or omit
to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of
the circumstances then existing;

 

(i)
otherwise use commercially reasonable efforts to comply with all applicable rules and regulations of the SEC under the
Securities Act and the Exchange Act, including, without limitation, Rule 172 under the Securities Act, file any final
Prospectus, including any supplement or amendment thereof, with the SEC pursuant to Rule 424 under the Securities Act,
promptly inform NDX in writing if, at any time during the Effectiveness Period, the Company does not satisfy the conditions
specified in Rule 172 and, as a result thereof, NDX is required to deliver a Prospectus in connection with any disposition of
Registrable Securities and take such other actions as may be reasonably necessary to facilitate the registration of the
Registrable Securities hereunder; and make available to its security holders, as soon as reasonably practicable, but not
later than the Availability Date (as defined below), an earnings statement covering a period of at least twelve (12) months,
beginning after the effective date of each Registration Statement, which earnings statement shall satisfy the provisions of
Section 11(a) of the Securities Act, including Rule 158 promulgated thereunder (for the purpose of this subsection 3(i),
“Availability Date” means the 45th day following the end of the fourth fiscal quarter that includes the
effective date of such Registration Statement, except that, if such fourth fiscal quarter is the last quarter of the
Company’s fiscal year, “Availability Date” means the 90th day after the end of such fourth fiscal
quarter); and

 

(j)
With a view to making available to NDX the benefits of Rule 144 (or its successor rule) and any other rule or regulation of
the SEC that may at any time permit NDX to sell shares of Borrower Common Stock to the public without registration, the
Company covenants and agrees to: (i) make and keep public information available, as those terms are understood and defined in
Rule 144, until the earlier of (A) six months after such date as all of the Registrable Securities may be sold without
restriction by the holders thereof pursuant to Rule 144 or any other rule of similar effect or (B) such date as all of the
Registrable Securities shall have been resold pursuant to a Registration Statement, Rule 144 or otherwise in a transaction in
which the transferee receives freely tradable shares; (ii) file with the SEC in a timely manner all reports and other
documents required of the Company under the Exchange Act; and (iii) furnish to NDX upon request, as long as NDX owns any
Registrable Securities, (A) a written statement by the Company that it has complied with the reporting requirements of the
Exchange Act, (B) a copy of the Company’s most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q, and
(C) such other information as may be reasonably requested in order to avail NDX of any rule or regulation of the SEC that
permits the selling of any such Registrable Securities without registration.

 

    	 	-5-	 

    	 

    

 

4. Obligations
of NDX.

 

(a)
NDX shall furnish in writing to the Company such information regarding itself, the Registrable Securities held by it and the
intended method of disposition of the Registrable Securities held by it, as shall be reasonably required to effect the
registration of such Registrable Securities and shall execute such documents in connection with such registration as the
Company may reasonably request. At least five (5) Business Days prior to the first anticipated filing date of any
Registration Statement, the Company shall notify NDX of the information the Company requires from NDX if NDX elects to have
any of the Registrable Securities included in the Registration Statement. NDX shall provide such information to the Company
at least two (2) Business Days prior to the first anticipated filing date of such Registration Statement if NDX elects to
have any of the Registrable Securities included in the Registration Statement.

 

(b)
NDX, by its acceptance of the Registrable Securities agrees to cooperate with the Company as reasonably requested by the
Company in connection with the preparation and filing of a Registration Statement hereunder, unless NDX has notified the
Company in writing of its election to exclude all of its Registrable Securities from such Registration Statement.

 

(c)
NDX agrees that, upon receipt of any notice from the Company of either (i) the commencement of an Allowed Delay pursuant to
Section 2(c)(ii) or (ii) the happening of an event pursuant to Section 3(h) hereof, NDX will immediately discontinue
disposition of Registrable Securities pursuant to the Registration Statement covering such Registrable Securities, until NDX
is advised by the Company that such dispositions may again be made.

 

(d)
NDX agrees that it will not sell, dispose or otherwise transfer its Registrable Securities other than (i) pursuant to the
Plan of Distribution contained in the Registration Statement covering such Registrable Securities, (ii) in accordance with
the requirements of Rule 144 or (iii) in a transaction exempt from the registration requirements of the Securities Act and as
to which the Company has received an opinion of counsel reasonably satisfactory to it that such transfer may lawfully be made
without registration under the Securities Act.

 

    	 	-6-	 

    	 

    

 

5. Indemnification.

 

(a) Indemnification
by the Company. The Company will indemnify and hold harmless NDX and its officers, directors, members, managers,
partners, trustees, employees and agents and other representatives, successors and assigns, and each other person, if any,
who controls NDX within the meaning of the Securities Act, against any losses, claims, damages or liabilities, joint or
several, to which they may become subject under the Securities Act or otherwise, insofar as such losses, claims, damages or
liabilities (or actions in respect thereof) arise out of or are based upon: (i) any untrue statement or alleged untrue
statement or omission or alleged omission of any material fact contained in any registration statement, any prospectus, or
any amendment or supplement thereof; (ii) any blue sky application or other document executed by the Company specifically for
that purpose or based upon written information furnished by the Company filed in any state or other jurisdiction in order to
qualify any or all of the Registrable Securities under the securities laws thereof (any such application, document or
information herein called a “Blue Sky Application”); (iii) the omission or alleged omission to state in a
Blue Sky Application a material fact required to be stated therein or necessary to make the statements therein not
misleading; (iv) any violation by the Company or its agents of any rule or regulation promulgated under the Securities Act
applicable to the Company or its agents and relating to action or inaction required of the Company in connection with such
registration; or (v) any failure to register or qualify the Registrable Securities included in any such
Registration Statement in any state where the Company or its agents has affirmatively undertaken or agreed in writing that
the Company will undertake such registration or qualification on NDX’s behalf and will reimburse NDX, and each such
officer, director or member and each such controlling person for any legal or other expenses reasonably incurred by them in
connection with investigating or defending any such loss, claim, damage, liability or action; provided, however,
that the Company will not be liable in any such case if and to the extent that any such loss, claim, damage or liability
arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission so made in
conformity with information furnished by NDX or any such controlling person in writing specifically for use in such
registration statement or prospectus.

 

(b) Indemnification
by NDX. NDX agrees to indemnify and hold harmless, to the fullest extent permitted by law, the Company, its directors,
officers, employees, stockholders and each person who controls the Company (within the meaning of the Securities Act) against
any losses, claims, damages, liabilities and expense (including reasonable attorney fees) resulting from any untrue statement
of a material fact or any omission of a material fact required to be stated in the Registration Statement or Prospectus or
amendment or supplement thereto or necessary to make the statements therein not misleading, to the extent, but only to the
extent that such untrue statement or omission is contained in any information furnished in writing by NDX to the Company
specifically for inclusion in such Registration Statement or Prospectus or amendment or supplement thereto. In no event shall
the liability of NDX be greater in amount than the dollar amount of the proceeds (net of all expenses paid by NDX in
connection with any claim relating to this Section 5 and the amount of any damages NDX has otherwise been required to pay by
reason of such untrue statement or omission) received by NDX upon the sale of the Registrable Securities included in the
Registration Statement giving rise to such indemnification obligation.

 

    	 	-7-	 

    	 

    

 

(c) Conduct
of Indemnification Proceedings. Any person entitled to indemnification hereunder shall (i) give prompt notice to the
indemnifying party of any claim with respect to which it seeks indemnification and (ii) permit such indemnifying party to
assume the defense of such claim with counsel reasonably satisfactory to the indemnified party; provided that any
person entitled to indemnification hereunder shall have the right to employ separate counsel and to participate in the
defense of such claim, but the fees and expenses of such counsel shall be at the expense of such person unless (a) the
indemnifying party has agreed to pay such fees or expenses, or (b) the indemnifying party shall have failed to assume the
defense of such claim and employ counsel reasonably satisfactory to such person or (c) in the reasonable judgment of any such
person, based upon written advice of its counsel, a conflict of interest exists between such person and the indemnifying
party with respect to such claims (in which case, if the person notifies the indemnifying party in writing that such person
elects to employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the right
to assume the defense of such claim on behalf of such person); and provided, further, that the failure of any
indemnified party to give notice as provided herein shall not relieve the indemnifying party of its obligations hereunder,
except to the extent that such failure to give notice shall materially adversely affect the indemnifying party in the defense
of any such claim or litigation. It is understood that the indemnifying party shall not, in connection with any proceeding in
the same jurisdiction, be liable for fees or expenses of more than one separate firm of attorneys at any time for all
such indemnified parties. No indemnifying party will, except with the consent of the indemnified party, consent to entry of
any judgment or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant
or plaintiff to such indemnified party of a release from all liability in respect of such claim or litigation.

 

(d) Contribution.
If for any reason the indemnification provided for in the preceding paragraphs (a) and (b) is unavailable to an indemnified
party or insufficient to hold it harmless, other than as expressly specified therein, then the indemnifying party shall
contribute to the amount paid or payable by the indemnified party as a result of such loss, claim, damage or liability in
such proportion as is appropriate to reflect the relative fault of the indemnified party and the indemnifying party, as well
as any other relevant equitable considerations. No person guilty of fraudulent misrepresentation within the meaning of
Section 11(f) of the Securities Act shall be entitled to contribution from any person not guilty of such fraudulent
misrepresentation. In no event shall the contribution obligation of a holder of Registrable Securities be greater in amount
than the dollar amount of the proceeds (net of all expenses paid by such holder in connection with any claim relating to this
Section 5 and the amount of any damages such holder has otherwise been required to pay by reason of such untrue or alleged
untrue statement or omission or alleged omission) received by it upon the sale of the Registrable Securities giving rise to
such contribution obligation.

 

6. Miscellaneous.

 

(a) Amendments
and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived
(either generally or in a particular instance and either retroactively or prospectively), only with the written consent of
the Company and NDX.

 

(b) Notices.
All notices and other communications provided for or permitted hereunder shall be made as set forth in Section 10.12 of the
Credit Agreement.

 

    	 	-8-	 

    	 

    

 

(c) Assignments
and Transfers NDX. The provisions of this Agreement shall be binding upon and inure to the benefit of NDX and its
respective successors and assigns. NDX may transfer or assign, in whole or from time to time in part, to one or more persons
its rights hereunder in connection with the transfer of Registrable Securities by NDX to such person, provided that NDX
complies with all laws applicable thereto and provides written notice of assignment to the Company promptly after such
assignment is effected.

 

(d) Assignments
and Transfers by the Company. This Agreement may not be assigned by the Company (whether by operation of law or
otherwise) without the prior written consent of NDX; provided, however, that in the event that the
Company is a party to a merger, consolidation, share exchange or similar business combination transaction in which the
Borrower Common Stock is converted into the equity securities of another Person, from and after the effective time of such
transaction, such Person shall, by virtue of such transaction, be deemed to have assumed the obligations of the Company
hereunder, the term “Company” shall be deemed to refer to such Person and the term “Registrable
Securities” shall be deemed to include the securities received by NDX in connection with such transaction unless such
securities are otherwise freely tradable by NDX after giving effect to such transaction.

 

(e) Benefits
of this Agreement. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the
respective successors and permitted assigns of the parties. Nothing in this Agreement, express or implied, is intended to
confer upon any party other than the parties hereto or their respective successors and permitted assigns any rights,
remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this
Agreement.

 

(f) Counterparts;
Faxes. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. This Agreement may be delivered via facsimile or other form of
electronic communication, which shall be deemed an original.

 

(g) Titles
and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be
considered in construing or interpreting this Agreement.

 

(h) Severability.
Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be
ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof but
shall be interpreted as if it were written so as to be enforceable to the maximum extent permitted by applicable law, and any
such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any
other jurisdiction. To the extent permitted by applicable law, the parties hereby waive any provision of law which renders
any provisions hereof prohibited or unenforceable in any respect.

 

(i) Further
Assurances. The parties shall execute and deliver all such further instruments and documents and take all such other
actions as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment of
the agreements herein contained.

 

    	 	-9-	 

    	 

    

 

(j) Entire
Agreement. This Agreement is intended by the parties as a final expression of their agreement and intended to be a
complete and exclusive statement of the agreement and understanding of the parties hereto in respect of the subject matter
contained herein. This Agreement supersedes all prior agreements and understandings between the parties with respect to such
subject matter.

 

(k) Governing
Law; Consent to Jurisdiction; Waiver of Jury Trial. This Agreement shall be governed by, and construed in accordance
with, the internal laws of the State of New York without regard to the choice of law principles thereof. Each of the parties
hereto irrevocably submits to the exclusive jurisdiction of the courts of the State of New York located in New York County
and the United States District Court for the Southern District of New York for the purpose of any suit, action, proceeding or
judgment relating to or arising out of this Agreement and the transactions contemplated hereby. Service of process in
connection with any such suit, action or proceeding may be served on each party hereto anywhere in the world by the same
methods as are specified for the giving of notices under this Agreement. Each of the parties hereto irrevocably consents to
the jurisdiction of any such court in any such suit, action or proceeding and to the laying of venue in such court. Each
party hereto irrevocably waives any objection to the laying of venue of any such suit, action or proceeding brought in such
courts and irrevocably waives any claim that any such suit, action or proceeding brought in any such court has been brought
in an inconvenient forum. EACH OF THE PARTIES HERETO WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH
RESPECT TO OR ARISING OUT OF THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY AND REPRESENTS THAT COUNSEL HAS BEEN
CONSULTED SPECIFICALLY AS TO THIS WAIVER.

 

    	 	-10-	 

    	 

    

 

EXECUTION
VERSION

 

IN
WITNESS WHEREOF, the parties have executed this Agreement or caused their duly authorized officers to execute this Agreement as
of the date first above written.

 

	The Company:	CANCER
    GENETICS, INC.
	 	 
	 	By:	/s/
    John A. Roberts
	 	Name:
    	John
    A. Roberts
	 	Title:
    	Chief
    Executive Officer

 

[Signature
Page to Registration Rights Agreement]

 

    	 	 	 

    	 

    

 

	NDX:	NOVELLUSDX,
    LTD.
	 	 
	 	By:	/s/
    Haim Gil-Ad 
	 	Name:
    	Haim
    Gil-Ad
	 	Title:
    	Chief
    Executive Officer

 

[Signature
Page to Registration Rights Agreement]

 

    	 	 	 

    	 

    

 

EXECUTION
VERSION

 

Exhibit
A

 

Plan
of Distribution

 

The
selling stockholders, which as used herein includes donees, pledgees, transferees or other successors-in-interest selling shares
of common stock or interests in shares of common stock received after the date of this prospectus from NDX or another selling
stockholder as a gift, pledge, partnership distribution or other transfer, may, from time to time, sell, transfer or otherwise
dispose of any or all of their shares of common stock or interests in shares of common stock on any stock exchange, market or
trading facility on which the shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing
market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time
of sale, or at negotiated prices.

 

The
selling stockholders may use any one or more of the following methods when disposing of shares or interests therein:

 

	 	–	ordinary
    brokerage transactions and transactions in which the broker-dealer solicits purchasers;
	 	–	block
    trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block
    as principal to facilitate the transaction;
	 	–	purchases
    by a broker-dealer as principal and resale by the broker-dealer for its account;
	 	–	an
    exchange distribution in accordance with the rules of the applicable exchange;
	 	–	privately
    negotiated transactions;
	 	–	short
    sales effected after the date the registration statement of which this Prospectus is a part is declared effective by the SEC;
	 	–	through
    the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;
	 	–
	broker-dealers
    may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share;
	 	–	a
    combination of any such methods of sale; and
	 	–	any
    other method permitted by applicable law.

 

The
selling stockholders may, from time to time, pledge or grant a security interest in some or all of the shares of common stock
owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer
and sell the shares of common stock, from time to time, under this prospectus, or under an amendment to this prospectus under
Rule 424(b)(3) or other applicable provision of the Securities Act amending the list of selling stockholders to include the pledgee,
transferee or other successors in interest as selling stockholders under this prospectus. The selling stockholders also may transfer
the shares of common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will
be the selling beneficial owners for purposes of this prospectus.

 

    	 	 	 

    	 

    

 

In
connection with the sale of our common stock or interests therein, the selling stockholders may enter into hedging transactions
with broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in the course
of hedging the positions they assume. The selling stockholders may also sell shares of our common stock short and deliver these
securities to close out their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these
securities. The selling stockholders may also enter into option or other transactions with broker-dealers or other financial institutions
or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution
of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this
prospectus (as supplemented or amended to reflect such transaction).

 

The
aggregate proceeds to the selling stockholders from the sale of the common stock offered by them will be the purchase price of
the common stock less discounts or commissions, if any. Each of the selling stockholders reserves the right to accept and, together
with their agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly
or through agents. We will not receive any of the proceeds from this offering.

 

The
selling stockholders also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under
the Securities Act of 1933, provided that they meet the criteria and conform to the requirements of that rule.

 

The
selling stockholders and any underwriters, broker-dealers or agents that participate in the sale of the common stock or interests
therein may be “underwriters” within the meaning of Section 2(11) of the Securities Act. Any discounts, commissions,
concessions or profit they earn on any resale of the shares may be underwriting discounts and commissions under the Securities
Act. Selling stockholders who are “underwriters” within the meaning of Section 2(11) of the Securities Act will be
subject to the prospectus delivery requirements of the Securities Act.

 

To
the extent required, the shares of our common stock to be sold, the names of the selling stockholders, the respective purchase
prices and public offering prices, the names of any agents, dealer or underwriter, any applicable commissions or discounts with
respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective
amendment to the registration statement that includes this prospectus.

 

In
order to comply with the securities laws of some states, if applicable, the common stock may be sold in these jurisdictions only
through registered or licensed brokers or dealers. In addition, in some states the common stock may not be sold unless it has
been registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied
with.

 

    	 	-2-	 

    	 

    

 

We
have advised the selling stockholders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales
of shares in the market and to the activities of the selling stockholders and their affiliates. In addition, to the extent applicable
we will make copies of this prospectus (as it may be supplemented or amended from time to time) available to the selling stockholders
for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify
any broker-dealer that participates in transactions involving the sale of the shares against certain liabilities, including liabilities
arising under the Securities Act.

 

We
have agreed to indemnify the selling stockholders against liabilities, including liabilities under the Securities Act and state
securities laws, relating to the registration of the shares offered by this prospectus.

 

We
have agreed with the selling stockholders to keep the registration statement of which this prospectus constitutes a part effective
until the earlier of (i) the date that such securities become eligible for resale without volume or manner-of-sale restrictions
and without current public information pursuant to Rule 144 and certain other conditions have been satisfied, or (ii) all of the
securities have been sold or otherwise disposed of pursuant to the registration statement of which this prospectus forms a part
or in a transaction in which the transferee receives freely tradable shares.

 

    	 	-3-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}]]